Results 131 to 140 of about 261,105 (346)

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors [PDF]

open access: bronze, 1999
Everett E. Vokes   +5 more
openalex   +1 more source

History of Paclitaxel and Oral Paclitaxel – Clinical Data and Future [PDF]

open access: yesIndian Journal of Medical and Paediatric Oncology, 2020
Ganesh H Divekar   +2 more
openaire   +2 more sources

Targeted Delivery of CNS‐Specific Hesperidin as a Leptin Sensitizer for Treating Obesity‐Associated Sleep‐Disordered Breathing

open access: yesAdvanced Science, EarlyView.
Hesperidin nanoparticles (HE NPs) effectively combat obesity and sleep‐disordered breathing in mice by enhancing leptin sensitivity. Through suppression of hypothalamic endoplasmic reticulum stress and restoration of leptin signaling, HE NPs promote weight loss and improve breathing during sleep.
Yixuan Wang   +11 more
wiley   +1 more source

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group [PDF]

open access: green, 1996
Jan P. van Meerbeeck   +11 more
openalex   +1 more source

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

open access: yesNew England Journal of Medicine, 2013
D. V. Von Hoff   +22 more
semanticscholar   +1 more source

APOL2 Stabilizes Ku80 to Confer NHEJ‐Mediated Radioresistance in Gastric Cancer

open access: yesAdvanced Science, EarlyView.
Radiotherapy resistance in gastric cancer (GC) is often mediated by enhanced DNA repair. APOL2 is found to promote NHEJ by stabilizing Ku80, conferring radioresistance. High APOL2 correlates with poor prognosis. Formononetin disrupts APOL2‐Ku80, restoring radiosensitivity, suggesting a novel therapeutic strategy.
Dan Zu   +23 more
wiley   +1 more source

Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells

open access: yesBMC Cancer
Background Paclitaxel, a tubulin-binding agent, is a Food and Drug Administration-approved first-line drug for the treatment of non-small cell lung cancer (NSCLC), for both squamous and non-squamous cell lung carcinoma, with paclitaxel/carboplatin ...
Yanyan Lu   +3 more
doaj   +1 more source

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium [PDF]

open access: bronze, 1999
Christopher J. Sweeney   +7 more
openalex   +1 more source

CGRP‐Loaded ROS‐Responsive Hydrogel Restores Neuro‐Angiogenic Signaling to Promote Bone Regeneration in Diabetes‐Associated Periodontitis

open access: yesAdvanced Science, EarlyView.
This study shows that diabetes damages sensory nerve fibers, especially CGRP‐positive ones, in the periodontium and disrupts autophagy in trigeminal ganglion neurons, affecting bone homeostasis by inhibiting type H vessel formation. To address this, CGRP@PVA/tsPBA hydrogels are developed to release CGRP in response to ROS, which binds to endothelial ...
Chaoning Zhan   +7 more
wiley   +1 more source

Paclitaxel

open access: yesRevista de Medicina de la Universidad de Navarra, 2017
M, Díaz, M A, Campanero
openaire   +2 more sources

Home - About - Disclaimer - Privacy